Welcome to our dedicated page for Bausch Health Companies SEC filings (Ticker: BHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bausch Health Companies Inc. filings document regulatory disclosures for a global diversified pharmaceutical company incorporated in British Columbia. The record includes Form 8-K reports for quarterly and annual operating results, Regulation FD updates, clinical-program disclosures, material agreements, debt exchanges and credit-agreement refinancing involving Bausch Health and its subsidiaries, including Bausch + Lomb.
Proxy materials describe annual meeting matters, director elections, auditor approval, executive compensation votes and governance procedures. Other current reports address compensatory arrangements, including performance share unit settlement terms, and capital-structure disclosures tied to senior secured notes, guarantees, collateral arrangements and refinancing transactions.
Bausch Health Companies Inc. director reported receiving an equity-based compensation award for board service. On December 31, 2025, the director acquired 4,586 restricted share units, each representing a contingent right to receive one common share of the company with no par value. These units were issued in lieu of cash compensation for serving on the board for the quarter ending December 31, 2025. Following this award, the director beneficially owned 38,408 common shares on a direct basis.
Bausch Health Companies Inc. reported that one of its directors received equity compensation for board service for the quarter ending December 31, 2025. The director was granted 989 restricted share units, each representing a contingent right to receive one common share with no par value, issued in lieu of cash compensation. After this grant, the reporting person beneficially owned 266,441 common shares, held directly.
Bausch Health Companies Inc. completed previously announced exchange offers, issuing $1.6 billion aggregate principal amount of new 10.00% Senior Secured Notes due 2032 through its indirect wholly owned subsidiary 1261229 B.C. Ltd. These new notes were exchanged for outstanding 4.875% and 11.00% Senior Secured Notes due 2028 under terms described in a confidential exchange offer memorandum.
The new 2032 notes were issued under an existing indenture structure and form a single series with $4.4 billion principal amount of the Issuer’s existing 10.00% Senior Secured Notes due 2032, sharing the same terms except for interest accrual, consideration and temporary securities identifiers. In connection with this issuance, an additional 26,495,472 common shares of Bausch + Lomb Corporation were pledged, bringing the Issuer’s pledged stake to 211,963,893 shares, representing approximately 60% of Bausch + Lomb’s outstanding common shares as of the settlement date. The existing and new notes are secured by a first priority lien on substantially all assets of the Issuer and other guarantors, including this equity stake.
Bausch Health Companies Inc. reported the final results and expiration of its previously announced debt exchange offers. The company had offered holders of its outstanding 4.875% and 11.00% Senior Secured Notes due 2028 the option to exchange into up to $1.6 billion aggregate principal amount of new 10.00% Senior Secured Notes due 2032, to be issued by its indirect wholly owned subsidiary 1261229 B.C. Ltd. These exchanges were conducted under the terms of a confidential exchange offer memorandum dated November 24, 2025, and expired at 5:00 p.m. New York City time on December 23, 2025. Additional details on the final exchange results are provided in a press release attached as an exhibit.
Bausch Health Companies Inc. reported that its subsidiary Bausch + Lomb Corporation has allocated a new $2,802,125,000 tranche of term B loans, called the Replacement Term Loans, to refinance its existing term B loans due 2031 and 2028. The new loans are expected to carry an applicable margin of 3.75% per annum for loans tied to term SOFR and 2.75% per annum for loans tied to the alternate base rate.
The margins represent a 0.50% per annum reduction versus the existing Third Amendment Term Loans and a 0.25% per annum reduction versus the First Incremental Term Loans. The Replacement Term Loans will mature on January 15, 2031, maintaining the current 2031 maturity while extending the former 2028 maturity. The transactions are anticipated to close in the first quarter of 2026, though completion on these terms is not assured.
Bausch Health Companies Inc. reported the early results of its previously announced debt exchange offers. The company is offering to exchange its outstanding 4.875% Senior Secured Notes due 2028 and 11.00% Senior Secured Notes due 2028 for up to $1.6 billion aggregate principal amount of new 10.00% Senior Secured Notes due 2032, to be issued by indirect wholly owned subsidiary 1261229 B.C. Ltd., under the terms described in a confidential exchange offer memorandum dated November 24, 2025. The update covers early participation results as of 5:00 p.m. New York City time on December 8, 2025, as detailed in an accompanying press release. The company also notes that the new notes will not be registered under U.S. or Canadian public offering rules and may only be offered or sold under applicable exemptions.
Bausch Health Companies Inc. insider filing reports a large share purchase by a major shareholder’s managed funds. On 11/25/2025, investment funds managed by Paulson & Co. acquired 2,500,000 shares of Bausch Health common stock at $6.25 per share. After this transaction, the funds collectively held 73,255,869 shares, reported as indirectly owned "By Managed Funds." The reporting person is identified as a director and 10% owner, and the filing notes that Paulson & Co. and John Paulson may be deemed indirect beneficial owners through their roles with the funds, while formally disclaiming beneficial ownership beyond any pecuniary interest.
Bausch Health Companies Inc. (BHC) has launched exchange offers to swap its outstanding 4.875% and 11.00% Senior Secured Notes due 2028 for up to $1.6 billion aggregate principal amount of new 10.00% Senior Secured Notes due 2032 issued by an indirect subsidiary. The new notes will form a single series with an existing $4.4 billion tranche of 10.00% Senior Secured Notes due 2032 issued earlier in 2025.
Participation is limited to eligible institutional and non‑U.S. holders under U.S. and international securities laws, and acceptances will target a mix of approximately 52.6% 11.00% notes and 47.4% 4.875% notes, subject to a maximum of $1.6 billion. Holders representing about $1,545 million of existing notes, or roughly 46% of the total outstanding, have signed a transaction support agreement committing to tender their notes and to take commercially reasonable actions to facilitate completion of the offers.
Nomura Holdings filed an amended Schedule 13G reporting beneficial ownership of Bausch Health Companies Inc. common shares. Through wholly owned subsidiary Nomura Global Financial Products, Inc., the group reports beneficial ownership of 15,708,085 shares, representing 4.2% of the class.
The filing lists shared voting and dispositive power over 15,708,085 shares and no sole voting or dispositive power. The percentage is based on 370,473,221 shares outstanding as of September 30, 2025, as disclosed by the issuer. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Bausch Health Companies Inc. reported stronger Q3 2025 results. Revenue reached $2.681 billion versus $2.510 billion a year ago, and operating income rose to $619 million from $318 million. Net income attributable to Bausch Health was $179 million, compared with a loss of $85 million, translating to diluted EPS of $0.48.
For the first nine months, revenue was $7.470 billion and net income attributable to Bausch Health was $269 million with diluted EPS of $0.72. Operating cash flow was $905 million. Cash and cash equivalents were $1.308 billion, and total assets were $26.824 billion.
Debt and equity shifted due to refinancing: current portion of long-term debt decreased to $579 million from $2.674 billion, while non‑current long-term debt increased to $20.463 billion. Total equity improved to $356 million from a deficit of $(322) million at year‑end. The company acquired DURECT for $84 million, expensing $81 million as acquired IPR&D tied to Larsucosterol. Bausch + Lomb remained approximately 88% owned, and the company continues to evaluate completing the B+L separation.
Common shares outstanding were 370,516,926 as of October 24, 2025.